Imidafenacin HCl

• CAT Number: I029259
• CAS Number: 893421-54-0
• Molecular Formula: C20H22ClN3O
• Molecular Weight: 355.86
• Purity: 98%
• Synonyms: Imidafenacin hydrochloride; Imidafenacin HCl; KRP-197 hydrochloride; ONO-8025 hydrochloride
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: 2-Methyl-a,a-diphenyl-1H-imidazole-1-butanamide hydrochloride
• InChI: InChI=1S/C20H21N3O.ClH/c1-16-22-13-15-23(16)14-12-20(19(21)24,17-8-4-2-5-9-17)18-10-6-3-7-11-18;/h2-11,13,15H,12,14H2,1H3,(H2,21,24);1H
• InChIKey: KOVKCGOEUKOSFQ-UHFFFAOYSA-N
• SMILES: O=C(N)C(C1=CC=CC=C1)(C2=CC=CC=C2)CCN3C=CN=C3C.[H]Cl

Imidafenacin HCl is a potent antimuscarinic agent, exhibiting selectivity toward muscarinic M3 receptors.

Reference

1: Yoshida M, Kato D, Nishimura T, Van Schyndle J, Uno S, Kimura T. Anticholinergic burden in the Japanese elderly population: Use of antimuscarinic medications for overactive bladder patients. Int J Urol. 2018 Aug 1. doi: 10.1111/iju.13758. [Epub ahead of print] PubMed PMID: 30069973.
2: Shin TH, Im SH, Goh MS, Lee ES, Ho MJ, Kim CH, Kang MJ, Choi YW. Novel Extended-Release Multiple-Unit System of Imidafenacin Prepared by Fluid-Bed Coating Technique. AAPS PharmSciTech. 2018 Jun 21. doi: 10.1208/s12249-018-1100-6. [Epub ahead of print] PubMed PMID: 29931609.
3: Yamada S, Ito Y, Nishijima S, Kadekawa K, Sugaya K. Basic and clinical aspects of antimuscarinic agents used to treat overactive bladder. Pharmacol Ther. 2018 Apr 27. pii: S0163-7258(18)30073-1. doi: 10.1016/j.pharmthera.2018.04.010. [Epub ahead of print] Review. PubMed PMID: 29709423.
4: Yoshida M, Takeda M, Gotoh M, Nagai S, Kurose T. Vibegron, a Novel Potent and Selective β(3)-Adrenoreceptor Agonist, for the Treatment of Patients with Overactive Bladder: A Randomized, Double-blind, Placebo-controlled Phase 3 Study. Eur Urol. 2018 May;73(5):783-790. doi: 10.1016/j.eururo.2017.12.022. Epub 2018 Feb 1. PubMed PMID: 29366513.
5: Kato D, Uno S, Van Schyndle J, Fan A, Kimura T. Persistence and adherence to overactive bladder medications in Japan: A large nationwide real-world analysis. Int J Urol. 2017 Oct;24(10):757-764. doi: 10.1111/iju.13422. Epub 2017 Aug 22. PubMed PMID: 28833621.
6: Cho S, Kwon SS, Lee KW, Yoo TK, Shin DG, Kim SW, Bae JH, Choi H, Kim YH. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms. Int J Clin Pract. 2017 May;71(5). doi: 10.1111/ijcp.12938. PubMed PMID: 28508455.
7: Yamanishi T, Asakura H, Seki N, Tokunaga S. Efficacy and safety of combination therapy with tamsulosin, dutasteride and imidafenacin for the management of overactive bladder symptoms associated with benign prostatic hyperplasia: A multicenter, randomized, open-label, controlled trial (DIrecT Study). Int J Urol. 2017 Jul;24(7):525-531. doi: 10.1111/iju.13359. Epub 2017 May 2. PubMed PMID: 28466585.
8: Sugiyama R, Aizawa N, Ito H, Fujimura T, Suzuki M, Nakagawa T, Fukuhara H, Kume H, Homma Y, Igawa Y. Synergic Suppressive Effect of Silodosin and Imidafenacin on Non-Voiding Bladder Contractions in Male Rats with Subacute Bladder Outlet Obstruction. Low Urin Tract Symptoms. 2017 May;9(2):94-101. doi: 10.1111/luts.12109. Epub 2015 Jul 27. PubMed PMID: 28394493.
9: Sugiyama H, Uemura O, Mori T, Okisio N, Unai K, Liu M. Effect of imidafenacin on the urodynamic parameters of patients with indwelling bladder catheters due to spinal cord injury. Spinal Cord. 2017 Feb;55(2):187-191. doi: 10.1038/sc.2016.168. Epub 2016 Nov 29. PubMed PMID: 27897185; PubMed Central PMCID: PMC5308215.
10: Ito Y, Kuraoka S, Endo S, Takahashi A, Onoue S, Yamada S. Urinary Excretion Contributes to Long-Lasting Blockade of Bladder Muscarinic Receptors by Imidafenacin: Effect of Bilateral Ureteral Ligation. J Pharmacol Exp Ther. 2017 Jan;360(1):69-74. Epub 2016 Nov 9. PubMed PMID: 27831487.
11: Yamazaki T, Fukata A, Muraki Y. Imidafenacin exerts the antidiuretic effect by enhancing vasopressin-related responses in orally water-loaded rats. Eur J Pharmacol. 2016 Nov 15;791:72-77. doi: 10.1016/j.ejphar.2016.08.021. Epub 2016 Aug 25. PubMed PMID: 27568834.
12: Otsuka A, Kageyama S, Suzuki T, Matsumoto R, Nagae H, Kitagawa M, Furuse H, Ozono S. Comparison of mirabegron and imidafenacin for efficacy and safety in Japanese female patients with overactive bladder: A randomized controlled trial (COMFORT study). Int J Urol. 2016 Dec;23(12):1016-1023. doi: 10.1111/iju.13231. Epub 2016 Sep 29. PubMed PMID: 27686226.
13: Kuraoka S, Ito Y, Wakuda H, Shinozuka K, Onoue S, Yamada S. Characterization of muscarinic receptor binding by the novel radioligand, [(3)H]imidafenacin, in the bladder and other tissues of rats. J Pharmacol Sci. 2016 Jul;131(3):184-9. doi: 10.1016/j.jphs.2016.06.002. Epub 2016 Jun 23. PubMed PMID: 27430986.
14: Torimoto K, Matsushita C, Yamada A, Goto D, Matsumoto Y, Hosokawa Y, Miyake M, Aoki K, Hirayama A, Tanaka N, Fujimoto K. Clinical efficacy and safety of mirabegron and imidafenacin in women with overactive bladder: A randomized crossover study (the MICRO study). Neurourol Urodyn. 2017 Apr;36(4):1097-1103. doi: 10.1002/nau.23050. Epub 2016 Jun 6. PubMed PMID: 27265880.
15: Thiagamoorthy G, Cardozo L, Robinson D. Current and future pharmacotherapy for treating overactive bladder. Expert Opin Pharmacother. 2016 Jul;17(10):1317-25. doi: 10.1080/14656566.2016.1186645. Epub 2016 Jun 2. Review. PubMed PMID: 27253972.
16: Ogoda M, Ito Y, Fuchihata Y, Onoue S, Yamada S. Characterization of muscarinic and P2X receptors in the urothelium and detrusor muscle of the rat bladder. J Pharmacol Sci. 2016 May;131(1):58-63. doi: 10.1016/j.jphs.2016.04.020. Epub 2016 Apr 26. PubMed PMID: 27174863.
17: Fukata A, Yamazaki T. Comparative Influence of Imidafenacin and Oxybutynin on Voiding Function in Rats with Functional Urethral Obstruction. Drug Res (Stuttg). 2016 Jun;66(6):306-11. doi: 10.1055/s-0035-1569410. Epub 2016 Mar 15. PubMed PMID: 26979753.
18: Suekane S, Ueda K, Suyama S, Hayashi T, Toyozawa N, Yoshitake M, Nishihara K, Sakashita N, Uchimura N, Matsuoka K. Comprehensive Health-Related Quality of Life is Influenced by Nocturia and Sleep Disturbance: Investigation Based on the SF-8. Kurume Med J. 2016;62(1-2):9-16. doi: 10.2739/kurumemedj.MS64010. Epub 2016 Mar 1. PubMed PMID: 26935441.
19: Muraki Y. Comparative functional selectivity of imidafenacin and propiverine, antimuscarinic agents, for the urinary bladder over colon in conscious rats. Naunyn Schmiedebergs Arch Pharmacol. 2015 Nov;388(11):1171-8. doi: 10.1007/s00210-015-1155-9. Epub 2015 Jul 28. PubMed PMID: 26216447.
20: Yamanishi T, Kaga K, Fuse M, Shibata C, Kamai T, Uchiyama T. The role of muscarinic receptor subtypes on carbachol-induced contraction of normal human detrusor and overactive detrusor associated with benign prostatic hyperplasia. J Pharmacol Sci. 2015 Jun;128(2):65-70. doi: 10.1016/j.jphs.2015.05.005. Epub 2015 May 27. PubMed PMID: 26084660.